June 29, 2012
-- The central nervous system is a fundamental part of the human body's response system, creating a massive range of reactions, targets, and in turn, diseases. With increasing average life expectancy, this wide range of disorders (from Alzheimer’s, to Parkinson’s, MS, dementia and depression), is becoming increasingly widespread in the population creating an ever greater need for new treatments and therapies.
Clinical trials are still an important area of discussion, with increasing efficiency in R&D and clinical trials as an essential part of the pharma industry. Clinical trials in the CNS industry must therefore operate a minefield of varying regulations and logistical difficulties, in order to develop a drug from discovery to market.
Johan Luthman, Senior Programme Leader Merck & Co. will speak at SMi’s Clinical Trials in CNS event held in London on the 5th & 6th November on the new opportunities to follow brain function and dysfunction a research on Alzheimers’s disease. He will discuss the critical AD biomarker validation and qualification work done via public-private pre competitive partnerships and detecting very early stages of AD pathology and following the disease progression with new technologies.
Register today to hear about the current development in neurodegenerative treatments from top pharma companies and academics. For further information and to register visit http://www.smi-online.co.uk/goto/clinicaltrials-research9...
and quote PRLOG. Or contact Ninica Hussain on tel +44 0 207 827 6186 or email nhussain@smi-